c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
144 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Boditrectinib
CAS :Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.Formule :C23H24F2N6OCouleur et forme :SolidMasse moléculaire :438.47Glesatinib hydrochloride
CAS :Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H28ClF2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :656.16Vabametkib
CAS :Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.Formule :C29H34N12OCouleur et forme :SolidMasse moléculaire :566.66c-Met-IN-16
CAS :c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .Formule :C21H17F2N9OCouleur et forme :SolidMasse moléculaire :449.42Mifanertinib
CAS :Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C21H19ClF3N5O2Couleur et forme :SolidMasse moléculaire :465.86Axl-IN-8
CAS :Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Formule :C31H29FN6O3Couleur et forme :SolidMasse moléculaire :552.6c-Met-IN-11
CAS :c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Formule :C30H20F2N4O3Couleur et forme :SolidMasse moléculaire :522.5LCRF-0004
CAS :LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Formule :C28H18F4N6O2SCouleur et forme :SolidMasse moléculaire :578.54AC-386
CAS :AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Formule :C35H34FN5O6Couleur et forme :SolidMasse moléculaire :639.67SAR125844
CAS :SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Formule :C25H23FN8O2S2Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :550.63Ref: TM-T5467
1mg34,00€5mg74,00€10mg110,00€25mg215,00€50mg344,00€100mg557,00€200mg790,00€1mL*10mM (DMSO)92,00€Mifanertinib dimaleate
CAS :Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C29H27ClF3N5O10Couleur et forme :SolidMasse moléculaire :698Tyrosine kinase-IN-4
CAS :Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].Formule :C23H21N3O3Couleur et forme :SolidMasse moléculaire :387.43Glesatinib
CAS :Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H27F2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.7Terevalefim
CAS :Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Formule :C9H8N2SDegré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :176.24Ref: TM-T37596
1mg52,00€5mg113,00€10mg200,00€25mg349,00€50mg510,00€100mg712,00€500mg1.459,00€1mL*10mM (DMSO)113,00€(rel)-Tivantinib
CAS :(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that areFormule :C23H19N3O2Couleur et forme :SolidMasse moléculaire :369.42Tyrosine kinase-IN-6
CAS :Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].Formule :C37H31F2N5O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :695.73SOMG-833 HCl
CAS :SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.Formule :C22H22F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :445.44c-met-IN-1
CAS :c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Formule :C35H37FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.7SOMCL-863
CAS :SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.
Formule :C23H24F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.46(3S,4S)-Tivantinib
CAS :(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in theFormule :C23H19N3O2Couleur et forme :SolidMasse moléculaire :369.42Entacapone acid
CAS :Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).Formule :C10H6N2O6Degré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :250.16OSI-296
CAS :OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.Formule :C21H19Cl2FN4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.3MET kinase-IN-3
CAS :MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.Formule :C25H16ClF2N5O2Couleur et forme :SolidMasse moléculaire :491.88Emzeltrectinib
CAS :Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C17H15F3N6OCouleur et forme :SolidMasse moléculaire :376.34Resencatinib
CAS :Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C30H29N7O3Couleur et forme :SolidMasse moléculaire :535.6met-kinase-in-2
CAS :MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.Formule :C33H27FN4O4Couleur et forme :SolidMasse moléculaire :562.59BPI-9016M
CAS :BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.Formule :C25H18F2N4O3Couleur et forme :SolidMasse moléculaire :460.43MK-2461
CAS :MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFormule :C24H25N5O5SDegré de pureté :95.41% - 99.67%Couleur et forme :SolidMasse moléculaire :495.55Ref: TM-T6094
1mg50,00€5mg114,00€10mg177,00€25mg344,00€50mg523,00€100mg798,00€200mg1.071,00€1mL*10mM (DMSO)127,00€Zongertinib
CAS :Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Formule :C29H29N9O2Degré de pureté :98.24%Couleur et forme :SolidMasse moléculaire :535.6Ref: TM-T69534
1mg66,00€5mg145,00€10mg222,00€25mg371,00€50mg522,00€100mg708,00€1mL*10mM (DMSO)170,00€EGFR-IN-8
CAS :EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC
Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02KRC-00715
CAS :KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.Formule :C25H25F3N8O3Couleur et forme :SolidMasse moléculaire :542.51c-Met-IN-26
CAS :c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formule :C24H19F2N9Couleur et forme :SolidMasse moléculaire :471.46SJF 8240
CAS :c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.
Formule :C58H65F2N7O11SCouleur et forme :SolidMasse moléculaire :1106.25c-Met-IN-2
CAS :c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Formule :C24H21FN10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :484.49Juvenile hormone B 3 (mixture of diastereomers)
CAS :Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.Formule :C16H26O4Couleur et forme :SolidMasse moléculaire :282.38KIN-8741
CAS :KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.Formule :C26H23F2N3O6Couleur et forme :SolidMasse moléculaire :511.47D6808
D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.Formule :C30H25F3N6O2Couleur et forme :SolidMasse moléculaire :558.55BMS-748730
CAS :BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.Formule :C22H26ClN7O3SCouleur et forme :SolidMasse moléculaire :504.01c-Met ligand-Linker Conjugate 2
CAS :c-Met ligand-Linker Conjugate 2 is a synthetic target protein ligand-linker complex used in the synthesis of PROTACs, such as PROTACc-Met degrader-6. PROTACc-Met degrader-6 is a c-Met PROTAC degrader that exhibits antitumor activity.Formule :C28H27N7O2Couleur et forme :SolidMasse moléculaire :493.563-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid
CAS :3-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid is a target protein ligand-linker conjugate combining a c-Met ligand with a PROTAC linker to recruit E3 ligase. It is applicable for synthesizing PROTACs, such as SJF-8240.Formule :C36H37F2N3O9Couleur et forme :SolidMasse moléculaire :693.69Zurletrectinib
CAS :Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.Formule :C19H19F2N7O2Couleur et forme :SolidMasse moléculaire :415.4PF-07265807
CAS :PF-07265807 is a highly efficient dual inhibitor of TAM and c-Met, IC50=6.1 nM, 13.2 nM, and 21.6 nM for AXL/MER/TOYRO3, cancer.Formule :C29H27F2N7O5Couleur et forme :SolidMasse moléculaire :591.57Tyrosine kinase inhibitor
CAS :Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Formule :C31H31FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.61Canlitinib
CAS :Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.
Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61
